US 7659280
2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
granted A61PA61P1/04A61P19/02
Quick answer
US patent 7659280 (2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases) held by Rigel Pharmaceuticals, Inc. expires Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Feb 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61P, A61P1/04, A61P19/02, A61P29/00, A61P37/00